ADPT
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp historical holders
total: 2
Viking Global Investors Adaptive Biotechnologies Corp transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Reduced:
- 2
- Held since:
- 2019 Q2
- Held for:
- 28 quarters
- Latest activity:
- 2020 Q4
Ole Andreas Halvorsen has been an institutional investor in Adaptive Biotechnologies Corp (ADPT) since 2019 Q2. According to 2026 Q1 report, Ole Andreas Halvorsen holds 29,993,708 shares with a market value of roughly $416.31M representing 1.16% of their equity portfolio. The fund/company first acquired ADPT in 2019 Q2, initially purchasing about 38.41M shares. Since the initial investment, Viking Global Investors has made 2 more transactions in this position.
Does Ole Andreas Halvorsen still hold ADPT?
Yes, Ole Andreas Halvorsen continues to hold Adaptive Biotechnologies Corp (ADPT). According to their 2026 Q1 report, they maintain a position of 29,993,708 shares valued at approximately $416.31M, representing 1.16% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in ADPT?
Ole Andreas Halvorsen first invested in Adaptive Biotechnologies Corp (ADPT) in 2019 Q2 at the reported quarter-end price of $48.30 per share, acquiring 38,406,607 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for ADPT?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Adaptive Biotechnologies Corp (ADPT) is approximately $48.30 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $48.30
- Weighted AVG sell price:
- $40.82
ADPT transactions history by Viking Global Investors
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.